DESTINY-Lung04 Shows PFS Benefit With Survival Unresolved

Company Daiichi Sankyo and AstraZeneca Event Type Clinical Trial Results (Phase III) Modality Antibody-Drug Conjugate (HER2-directed, topoisomerase-I inhibitor payload) Asset Trastuzumab Deruxtecan Target HER2 (exon 19/20 mutations) Disease Area HER2-Mutant Advanced Non-Small Cell Lung Cancer Summary First-line trastuzumab deruxtecan extended blinded-review median progression-free survival to…